A bacterial chassis patent claims an engineered microbial host organism designed to carry a gene construct, run a specific metabolic pathway, or produce a target metabolite under defined culture conditions. In this dataset, that includes claims tied to microorganism engineering (IPC C12N), fermentation and enzymatic synthesis (C12P), and, where the host is engineered for a therapeutic output, medicinal preparation claims (A61K). The common thread is that the organism itself, or the genetic construct inside it, is the subject of the claim rather than a downstream chemical process alone.

The assignee ranking behind this dataset covers 734 records, with the leading assignee holding 260 of them against 26 at fifth place and 15 at tenth — a steep drop that marks a genuine leadership tier rather than a flat field of similarly sized filers. The top five assignees combined hold 58.2% of all records in scope, and the top ten hold 69.6%. That concentration means a competitive read of this space should start with the leadership tier's specific claims rather than a broad market scan.

Filing activity rose through the late 2010s, peaked at 61 filings in 2021, and had fallen to 30 by 2024 — a documented -51% change over that three-year span. That decline is measured against 2024, the most recent year that can be treated as complete; 2025 and 2026 figures will keep rising as publications catch up, since publication typically lags filing by around 18 months. Read the recent years as incomplete rather than as evidence the field has stopped moving.

The clearest gaps sit outside the two dominant IPC classes: C12N (microorganism engineering, 59.9% of records) and A61K (medicinal preparations, 47.8%). Food and beverage applications under A23L cover only 6.8% of records, and plant-related engineering under A01H covers 4.1%, both well below the therapeutic-leaning core. A first claim in these branches — for example, a food-grade production chassis with a specific culture-condition limitation — faces materially less prior art than a general therapeutic chassis claim.

WO2025073895A1, filed by Univerza v Ljubljani and published 2025-04-10, claims strain improvement through a chromosomal deletion introduced near a target metabolic pathway or biosynthetic gene cluster, sized and positioned to alter expression of that cluster without disrupting the pathway. It is a positional-genomic-edit claim rather than a broad host-organism claim, so it primarily constrains other filers working on similarly targeted deletion strategies near biosynthetic gene clusters, not chassis engineering generally. Anyone designing a strain-improvement method with a comparable deletion strategy should read its claim scope closely before relying on a workaround.